GI

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Retrieved on: 
Wednesday, November 30, 2022

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy volunteers treated with multiple ascending doses of SYNB1353.  SYNB1353 is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the GI tract for the potential treatment of homocystinuria (HCU). 

Key Points: 
  • SYNB1353 is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the GI tract for the potential treatment of homocystinuria (HCU).
  • The Company also shared that the FDA has granted Orphan Drug Designation (ODD) to SYNB1353 for the treatment of HCU.
  • This dietary model was intended to capture in healthy volunteers a transient elevation in methionine following a meal challenge, in order to demonstrate proof of mechanism of consumption of methionine by SYNB1353.
  • Dosing of SYNB1353 resulted in a reduction in plasma methionine when measured over 24-hours as area under the curve (AUC) following a methionine meal challenge.

One GI Continues Eastern US Expansion

Retrieved on: 
Wednesday, November 30, 2022

Formed inApril 2020, One GI is comprised of leading gastroenterology practices throughoutthe Eastern US.

Key Points: 
  • Formed inApril 2020, One GI is comprised of leading gastroenterology practices throughoutthe Eastern US.
  • Goodwin Procterserved as exclusive legal counsel to One GI, and Alvarez & Marsal Transaction Advisory Group provided key diligence.
  • One GI is a gastroenterology healthcare services organization that partners with GI physicians to help them manage, optimize, and grow their practices.
  • One GI provides critical business services to physicians so they can focus on what they do best: providing excellent care to patients.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

Retrieved on: 
Wednesday, November 30, 2022

SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.

Key Points: 
  • Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific (excluding Japan and South Korea).
  • This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets.
  • Encorafenib in combination with cetuximab was approved by the FDA in April 2020 for previously treated patients with BRAF V600E-mutant mCRC.
  • HERKULES-3 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with GI cancers.

Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

Retrieved on: 
Wednesday, November 30, 2022

TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy.

Key Points: 
  • TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy.
  • Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions.
  • He will be responsible for spearheading the corporate development function, including guiding company strategy, tracking competitive and market developments, and identifying, negotiating and managing partnerships and potential acquisitions.
  • "I am delighted to join Chemomab at this exciting time in the company's development," said Dr. Jones.

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Retrieved on: 
Wednesday, November 30, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005402/en/
    PureTech announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTechs Glyph platform to be advanced toward the clinic.
  • The nomination of LYT-310 is an exciting expansion of PureTechs Glyph technology, said Daniel Bonner, Ph.D., Vice President at PureTech Health.
  • Glyph is PureTechs synthetic lymphatic-targeting chemistry platform which is designed to employ the lymphatic systems natural lipid absorption and transport process to enable the oral administration of certain therapeutics.
  • A second therapeutic candidate, LYT-310 (oral cannabidiol), is expected to enter the clinic in Q4 of 2023.

New GI Endoscopic Simulation-based Curricula to be Jointly Developed by the American Society for Gastrointestinal Endoscopy (ASGE) and Surgical Science

Retrieved on: 
Wednesday, November 30, 2022

DOWNERS GROVE, Ill., Nov. 30, 2022 /PRNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) is pleased to announce a collaboration with Surgical Science to develop new gastrointestinal endoscopy (GI) simulation-based training and curricula for GI fellows and advanced fellows, as well as general and advanced endoscopists.

Key Points: 
  • DOWNERS GROVE, Ill., Nov. 30, 2022 /PRNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) is pleased to announce a collaboration with Surgical Science to develop new gastrointestinal endoscopy (GI) simulation-based training and curricula for GI fellows and advanced fellows, as well as general and advanced endoscopists.
  • Initial focus will be on accelerating learning via simulated experience in endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP).
  • "ASGE is pleased to partner with Surgical Science to add simulation-based training to our portfolio of educational offerings for all segments of our membership."
  • ASGE provides a diverse, inclusive and engaged community to foster sharing, learning, advocacy and growth in GI endoscopy.

New GI Endoscopic Simulation-based Curricula to be Jointly Developed by the American Society for Gastrointestinal Endoscopy (ASGE) and Surgical Science

Retrieved on: 
Wednesday, November 30, 2022

DOWNERS GROVE, Ill., Nov. 30, 2022 /PRNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) is pleased to announce a collaboration with Surgical Science to develop new gastrointestinal endoscopy (GI) simulation-based training and curricula for GI fellows and advanced fellows, as well as general and advanced endoscopists.

Key Points: 
  • DOWNERS GROVE, Ill., Nov. 30, 2022 /PRNewswire/ -- The American Society for Gastrointestinal Endoscopy (ASGE) is pleased to announce a collaboration with Surgical Science to develop new gastrointestinal endoscopy (GI) simulation-based training and curricula for GI fellows and advanced fellows, as well as general and advanced endoscopists.
  • Initial focus will be on accelerating learning via simulated experience in endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP).
  • "ASGE is pleased to partner with Surgical Science to add simulation-based training to our portfolio of educational offerings for all segments of our membership."
  • ASGE provides a diverse, inclusive and engaged community to foster sharing, learning, advocacy and growth in GI endoscopy.

MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference

Retrieved on: 
Tuesday, November 29, 2022

MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites).

Key Points: 
  • MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites).
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
  • MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development

Retrieved on: 
Tuesday, November 29, 2022

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to license its Preecludia rule-out test for preeclampsia to Avero Diagnostics, formerly Northwest Pathology, for commercial development.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to license its Preecludia rule-out test for preeclampsia to Avero Diagnostics, formerly Northwest Pathology, for commercial development.
  • As we have shown, we remain committed to value creation from all our assets while Biora focuses on the progress of its therapeutics pipeline.
  • Under the terms of the agreement, Avero Diagnostics receives rights to assets and intellectual property related to the Preecludia test.
  • The Preecludia rule-out test for preeclampsia has the potential to be the first-of-its-kind test in the United States to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia.

Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video

Retrieved on: 
Thursday, November 17, 2022

Carlsbad, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announces the release of its new animated video for its lead asset in development, LB1148. The video can be accessed here.

Key Points: 
  • LB1148 is currently being developed for administration prior to GI surgeries requiring bowel resection, disrupting the intestinal epithelial barrier.
  • This animated video helps to showcase our innovative approach and explain in detail the mechanism of how we believe LB1148 works in protecting intestinal barrier heath, commented JD Finley, Interim Chief Executive Officer of Palisade Bio.
  • The LB1148 animated mechanism of action video is now available on the Companys website, here .
  • Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier.